CAPSUGEL TO HIGHLIGHT INNOVATIVE CAPSULE TECHNOLOGIES AND DOSAGE FORM SOLUTIONS AT THE 2014 AAPS ANNUAL MEETING AND EXPOSITION

October 23, 2014

  

CAPSUGEL TO HIGHLIGHT INNOVATIVE CAPSULE TECHNOLOGIES AND DOSAGE FORM SOLUTIONS AT THE 2014 AAPS ANNUAL MEETING AND EXPOSITION

Scientific posters, symposia and specialty seminars round out company’s presence

 

Morristown, N.J., October 23, 2014 – Capsugel scientists will discuss a range of advancements – including bioavailability enhancement and multi-particulate technologies, dry powder inhalation (DPI) technologies, and alternate-polymer and other specialized capsule technologies – at the 2014 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, which runs November 2-6 in San Diego, Calif. The company will also showcase specialized equipment to support key technologies in encapsulation and bioreactor process control.

 

"It’s an exciting time to be a scientist at Capsugel.  Our advanced science and engineering, expanded technology offerings, and the growing synergies between our Hard Capsule and Dosage Form Solutions (DFS) business units are leading to new opportunities to create value for our customers,” said Keith Hutchison, Ph.D., Senior Vice President, Research & Development, Capsugel. “At AAPS, we look forward to discussing our approach to addressing customers’ most-pressing formulation challenges, including low and variable drug absorption, high-potency/low-dose requirements and modified drug release profiles and to demonstrating our unique ability to design, develop and manufacture both state-of-the-art capsules and finished dosage forms."

 

Company scientists will present 20 technical posters and host a series of seminars on key innovations. Highlights include:

 

·         New lipid multi-particulate (LMP) technology, based on Capsugel’s proprietary melt-spray congeal processing, providing the functionality of lipid-based formulations with the patient and consumer benefits associated with a multi-particulate drug delivery;

·         Coni-Snap® sprinkle capsules designed for populations with swallowing difficulties, offering reproducible ease of opening for patients and caregivers;

·         Integrated formulation and specialized capsule offering for Inhalation products, including particle engineering for optimized formulations and specialized DPI capsules for pulmonary delivery;

·         Advancements in spray-dried dispersion and other bioavailability-enhancement technologies, pioneered by Bend Research, now a division of Capsugel Dosage Form Solutions.

 

Specialized equipment that will be featured at the booth includes Capsugel’s new Modular Automated Sampling Technology™ platform, or MAST, and its Xcelodose® precision powder micro-dosing system. MAST is an automated, aseptic bioreactor sampling system that will help advance the bioprocess industry toward real-time testing, predictive control and overall bioprocess guidance. Capsugel’s Xcelodose® system shortens drug development time, speeds first-in-human trials and lowers costs by reducing the need for formulation and stability studies before API proof of concept is established.

 

Visit Capsugel’s booth #1422 to learn about innovative dosage technology and manufacturing solutions for the pharmaceutical industry. An overview of poster presentations and seminars can be found here. Schedule a meeting with Capsugel in advance here, and follow updates about the meeting at www.capsugel.com.

 

ABOUT CAPSUGEL
Capsugel is a global leader in delivering high-quality, innovative dosage forms and solutions to its customers in the health care industry. The company’s Hard Capsule business offers customers the broadest portfolio of gelatin, vegetarian, and other specialized capsule technologies. Capsugel’s Dosage Form Solutions (DFS) business utilizes an array of proprietary technologies and specialized manufacturing capabilities to solve customers’ most pressing product development challenges, including bioavailability enhancement, modified release, abuse deterrence, biotherapeutic processing, and inhalation formulation. The company's fast-to-clinic program streamlines product development from pre-formulation through clinical and commercial supply for finished dosage forms. Headquartered in Morristown, N.J., Capsugel serves more than 4,000 customers in more than 100 countries. For additional information, visit www.capsugel.com.

# # #

For media inquiries, please contact Christina Chnaider at Christina.Chnaider@capsugel.com.